ALNY vs ZYME
ALNY: Alnylam is a global leader in RNA interference therapeutics, pioneering a new class of genetic medicines to treat rare and serious diseases. ZYME: A biotech company pioneering multispecific antibodies and ADCs for cancer and autoimmune disease, monetizing through a partnership-driven royalty aggregation model while advancing an internal pipeline.
Side-by-side fundamentals
| Metric | ALNY | ZYME | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $266.99 | $23.36 | |
| Market cap as of 2026-07-23 | $36.2B | $1.7B | |
| P/E as of 2026-07-23 | 62.77 | n/a | |
| PEG as of 2026-07-23 | 1.11 | n/a | |
| Net margin as of 2026-07-23 | +13.5% | -126.3% | ALNY higher |
| Gross margin as of 2026-07-23 | +80.8% | n/a | |
| Operating margin as of 2026-07-23 | +16.6% | -140.3% | ALNY higher |
| ROE as of 2026-07-23 | +98.3% | -37.8% | ALNY higher |
| ROA as of 2026-07-23 | +11.8% | -25.2% | ALNY higher |
| Debt / equity as of 2026-07-23 | 2.52 | 0.00 | ZYME lower |
| Revenue growth (YoY) as of 2026-07-23 | +82.6% | +3.3% | ALNY higher |
| Revenue CAGR (3y) SEC XBRL | +53.0% | -36.4% | ALNY higher |
| Beta as of 2026-07-23 | 0.24 | 1.14 | |
| 1-year return as of 2026-07-22 close | -15.3% | +63.1% | ZYME higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.